The lawsuit, spearheaded by Hagens Berman Sobol Shapiro LLP, targets a class period spanning January 14, 2025, to April 26, 2026. Plaintiffs contend that Erasca executives promoted ERAS-0015 as a superior molecular glue while allegedly obscuring critical risks. According to the complaint, the company used flawed preclinical comparisons to claim an edge over competitors like Revolution Medicines and failed to disclose looming patent infringement disputes.

The truth behind these claims reportedly surfaced in late April 2026, when Erasca acknowledged a legal challenge from Revolution Medicines and disclosed a patient death in its clinical trials. The news triggered a sharp decline in share price, resulting in a loss of over $2.8 billion in market capitalization. Reed Kathrein, a partner at Hagens Berman, stated the firm is investigating whether the company intentionally deceived investors about the drug's safety and its intellectual property moat. Shareholders who suffered significant losses during the specified period are encouraged to contact the firm to discuss their legal standing before the impending court deadline.